June 10, 2022
NervGen is featured in News Financial.
May 31, 2022
Health Europa features NervGen Pharma
April 7, 2022
Technology Networks features article by NervGen President & CEO, Paul Brennan
NervGen is featured in News Financial.
Health Europa features NervGen Pharma
Technology Networks features article by NervGen President & CEO, Paul Brennan
Interview with Paul Brennan, NervGen President & CEO (Interview at 29:22 in video)
BioPub webcast with NervGen.
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company’s initial focus is on Alzheimer’s, spinal cord injury and multiple sclerosis.
Contact
2955 Virtual Way
Suite 480
Vancouver, BC V5M 4X6
Phone: (778) 731-1711
Email: info@nervgen.com
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |